Objective: To determine whether changes in positron emission tomography (PET) avidity correlated with histologic response and were independently associated with outcome. Background: The implications of metabolic response to neoadjuvant therapy as measured by repeat PET imaging remain ill-defined for patients with gastric and gastroesophageal junction (GEJ) cancers. Methods: We identified patients with gastric and GEJ adenocarcinoma who were evaluated with PET imaging before and following neoadjuvant treatment, and subsequently underwent curative resections. Spearman rank correlation and Cox proportional hazards regression were used to evaluate standardized uptake value (SUV) and histologic response, pathologic parameters, and disease-specific survival (DSS). Results: From 2002 to 2013, 192 patients met our inclusion criteria. The median SUV max response was 57.3% (range: -110% to 100%) for patients with GEJ cancers, with a corresponding median pathologic treatment response of 80% (range: 0% to 100%). The median SUV max response was 32.5% (-230% to 100%) for patients with gastric cancers, with a corresponding median pathologic treatment response of 35% (range: 0% to 100%). The Spearman correlation between SUV max response and histologic response was significant for patients with GEJ (rho ¼ 0.19, P ¼ 0.04) and gastric (rho ¼ 0.44, P < 0.0001) cancers. For patients with GEJ (P <0.0001 to 0.046) and gastric cancers (P ¼ 0.0003 to 0.016), histopathologic response and tumor staging predicted DSS. SUV max response failed to demonstrate a relationship with DSS when entered into multivariable models containing conventional pathologic variables. Conclusion: Following completion of neoadjuvant therapy for gastric and GEJ adenocarcinoma, histopathologic staging remains the best predictor of outcome. Repeat post-treatment/preoperative PET imaging for the purpose of prognostication is of limited value.
18F
-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) imaging has historically been used to improve staging and identify occult metastatic disease for patients with gastrointestinal malignancies. 1 More recently, 18F-FDG PET/CT imaging has been used to deliver actionable information regarding tumor response to therapy. For gastric and gastroesophageal junction (GEJ) cancers, the increasing incorporation of neoadjuvant chemotherapy/chemoradiotherapy into the treatment plans of patients with clinically locally advanced disease has paved the way for repeat 18F-FDG PET/CT imaging to assess in vivo metabolic responses to therapy, as measured by changes in PET avidity, before definitive resection and pathologic evaluation. In 2007, the MUNICON II trial documented the utility of early repeat 18F-FDG PET/CT imaging in defining responders to treatment (>35% decrease in SUV uptake), and established this to be predictive of major histologic response and prognostic of survival. 2 More importantly, the MUNCON trial identified PET nonresponders to have a very poor prognosis. The Alliance for Clinical Trials in Oncology group is currently seeking to randomize PET nonresponders to either continuation or to changing neoadjuvant therapy before surgical resection, to see whether outcome in this very high-risk cohort can be improved.
Repeat 18F-FDG PET/CT imaging has been suggested to be prognostic in patients with GEJ and gastric cancer. Numerous studies have established an association between alterations in PET avidity and patient outcomes. [3] [4] [5] [6] [7] However, alterations in PET avidity following completion of neoadjuvant therapy can only be useful if the information is superior or supplemental to the forthcoming histopathologic evaluation of the resected tumor. No study to date has considered SUV response in the context of other known pathologic predictors of outcome, which will be imminently available to all treating physicians when repeat PET imaging is obtained after completion of neoadjuvant therapy and just before resection. We therefore sought to evaluate the prognostic utility of repeat preoperative 18F-FDG PET/CT imaging in patients with GEJ and gastric adenocarcinoma. Our aims were to correlate changes in SUV max with histopathologic response, to determine whether changes in SUV max after neoadjuvant therapy predicted outcomes, and to evaluate the ability of changes in SUVmax response to predict outcomes in the context of histopathologic data.
METHODS

Patients
We retrospectively reviewed our prospectively maintained database of all patients admitted to MSKCC for gastric and GEJ (Siewert II and III) 
PET Evaluation
PET/CT images were retrieved from our picture archiving and communication system (PACS) and analyzed using AW Software (GE Healthcare; Chicago, Illinois, USA). All PET/CT images were reviewed (by 2 radiologists, VB & HS) for hypermetabolic and nonhypermetabolic lesions using transaxial, coronal, and sagittal planes, as well as maximum intensity projection (MIP) images. Using a volumetric region of interest (ROI), SUV max for the primary lesion and any metastatic foci were obtained. SUV max for the gastric fundus and SUV mean values for liver were also calculated for normalization. Care was taken not to include any physiologic uptake or adjacent organs in the ROI. Uptake time (defined as time elapsed from injection of radiopharmaceutical to commencement of image acquisition) was noted for each time point and outliers (>20 minutes difference in postinjection time) were excluded from the study. Foreign PET/CT scans were also imported to our AW workstation and analyzed similarly to local PET/CT scans. Patients with foreign PET/CT scans with image quality issues, unavailable critical parameters (eg, time of injection), or problems with SUV calculations were excluded from the study (Supp. Figure 1 , http://links. lww.com/SLA/B312). Of note, all demographic data on patients including treatments, endoscopy, and biopsy results were available to the readers (VB and HS) at the time of image assessment. SUV max was recorded for all available PET scans. The baseline scan and the preoperative scan were used to determine the percentage change, which is reported as SUV max response.
Statistics
All analyses were performed stratified by site (GEJ and Gastric). The stratification of gastric and GE junction patients was performed to account for their different pre-surgery treatment regimens. Nearly all patients with gastric cancers received chemotherapy alone, while nearly all patients with GEJ cancers received both chemotherapy and radiation therapy. We postulated that this difference might be associated with a difference in SUV response in the primary tumor, histologic response in the primary tumor, and outcome, and therefore analyzed these cohorts of patients separately.
Descriptive statistics were calculated for clinical, histopathologic, and outcome variables. Medians and ranges were used for continuous variables, while frequencies and percent change were used to summarize categorical variables. Pathology stage was grouped as follows: stage 0-I, stage II, and stage III. T stage was grouped into T0-T1b versus T2, versus T3-T4b. For descriptive analyses, tumor type was grouped into diffuse versus other, and WHO type was grouped as signet ring versus other. Histologic tumor response was dichotomized by its empirical median value separately for each cohort. The SUV max response was correlated with histologic tumor response using Spearman rank correlation and visualized using scatter plots. For outcome analyses, SUV max was examined in 5 ways: (1) raw SUV max at baseline, (2) raw SUV max pre-surgery, (3) SUV max response (percent change), (4) SUV max dichotomized by its empirical median, and (5) SUV max dichotomized by previously established cut off of 35%. Kaplan-Meier methods were used to model the relationship between dichotomized histologic tumor response, and SUV max response with DSS for each site. Univariate Cox proportional hazards regression was used to assess the relationship between imaging and pathologic parameters, and disease-specific survival (DSS). DSS was defined as the time between resection and death, or date of recurrence for those patients alive with recurrence at the time of last follow-up; patients alive and recurrence-free were censored at last follow-up. The interaction between PET response and histologic tumor response was assessed for each cohort using Cox models. We examined the relationship between the change in SUV max and histologic tumor response in bivariate Cox analysis. We also examined the univariate relationship between site and DSS. In each cohort, multivariate models were built for PET response variables controlling for clinical and pathologic factors. Due to sample size constraints, clinical and pathologic variables significant at P < 0.05 were entered into a backwards selection model (stay criteria ¼ 0.10). Due to the inherent dependence of overall stage group on T stage and N stage, we only included T stage and N stage in the backward selection. Variables remaining after selection were included with PET/CT imaging parameters. P values below 0.05 were considered statistically significant. All analyses were performed using SAS 9.2; Cary, North Carolina, USA.
RESULTS
We identified 373 patients with GEJ and gastric cancers who received neoadjuvant therapy for locally advanced (!T3 or N1þ) cancers, had pre-treatment and preoperative PET imaging, and underwent curative resections at our institution during the study period. One hundred ninety-two patients, 120 with GEJ cancers, and 72 with gastric cancers met our eligibility criteria and were included in the study. Patients had a median age of 63 years (range: 24 to 84 years), and 73% (140/192) were men. Patient demographic and histopathologic data are reported in Table 1 , stratified by tumor location (GEJ vs gastric). Neoadjuvant chemotherapeutic regimens for patients with GEJ cancers consisted of cisplatin and irinotecan, while patients with gastric cancers were treated with epirubicin, cisplatin or oxaliplatin, and 5FU. PET scans were performed as a component of routine clinical care in 171 patients, and in the context of a prospective clinical trial in 21 patients. Median follow-up time for patients alive and disease-free at last evaluation was 36 months (range: 2.6 to 133.8 months).
SUV max Response and Histologic Tumor Response
GEJ
The median SUV max on the baseline and preoperative 18F-FDG PET/CT images for patients with GEJ cancers was 10.2 (range: 2 to 34) and 4.1 (range: 0 to 26.1), respectively. The median number of days between 18F-FDG PET/CT imaging was 119 days. The median SUV max response was 57.3% (range: -110% to 100%) for patients with GEJ cancers, with a corresponding median histologic tumor response of 80% (range: 0% to 100%). The Spearman correlation between SUV max response and histologic tumor response was significant (rho ¼ 0.19, P ¼ 0.04) for patients with GEJ cancers (Sup. Fig 2A, http://links.lww.com/SLA/B312).
Gastric
The median SUV max on the baseline and preoperative 18F-FDG PET/CT images for patients with gastric cancers was 7.4 (range: 2.3 to 28.9) and 4.5 (range: 0 to 33.2), respectively. The median number of days between 18F-FDG PET/CT imaging was 85 days. The median SUV max response was 32.5% (range: -230% to 100%), with a corresponding median histologic tumor response of
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Post-Treatment/Preoperative PET Response 35% (range: 0% to 100%). The Spearman correlation between SUV max response and histologic tumor response was significant (rho ¼ 0.44, P < 0.0001) for patients with gastric cancers (Sup. Fig 2B, http://links.lww.com/SLA/B312).
Disease-Specific Survival for GEJ Cancers
Histologic tumor response (continuous and dichotomized) was significantly associated with DSS (P ¼ 0.01, P ¼ 0.01, respectively) (Fig. 1A) . T stage (T3-4, vs T0-1, P ¼ 0.01), N stage (P < 0.0001), AJCC stage (III-IV vs 0-I, P < 0.0001), and LVI (P < 0.0001) were also found to be significantly associated with DSS (Table 2) . However, none of the SUV max variables were significantly associated with DSS (P ¼ 0.46 to 0.88) ( Table 2, Fig. 1B ).
Disease-Specific Survival for Gastric Cancers
Histologic tumor response (continuous) was significantly associated with DSS (P ¼ 0.02) ( Fig. 2A) . Similar to patients with GEJ cancers, T-stage (T3-T4 vs T0-1, P ¼ 0.01), N-stage (P ¼ 0.0006), AJCC stage (III-IV vs 0-I, P ¼ 0.0003), and LVI (P ¼ 0.002) were significantly associated with DSS for patients with gastric cancers (Table 3) . No SUV max variable was found to be significantly associated with DSS (P ¼ 0.10 to 0.52) ( Table 3 , Fig. 2B ).
Bivariate and Multivariable Analyses
In bivariate models with histologic tumor response and SUVmax response as predictors, histologic tumor response remained a significant predictor (P ¼ 0.007 and P ¼ 0.03, continuous), while SUV max response failed to reach significance (P ¼ 0.28 and P ¼ 0.55, continuous) for patients with GEJ and gastric cancers, respectively. Figure 3 depicts histologic tumor response against changes in SUV max response for each patient grouped by status at last follow-up. For illustrative purposes, only those with greater than 2 years of follow-up were considered ANED. Of note, there was no significant relationship between disease site (GEJ vs gastric) and DSS on univariate analysis (P ¼ 0.12).
Baseline pathologic multivariable models were built for GEJ and gastric patients separately. T stage, N stage, LVI, and histologic tumor response were entered into backwards selection models. After selection, only N stage (P ¼ 0.0005) and LVI (P ¼ 0.001) remained 
DISCUSSION
We have evaluated the utility of repeat preoperative 18F-FDG PET/CT imaging in the context of histopathologic data by reviewing the PET/CT scans, pathology, and outcomes for patients with GEJ and gastric adenocarcinoma treated at our institution since 2002. In doing so, our first aim was to correlate changes in SUV max with histologic tumor response. Assessing response to neoadjuvant therapy can be difficult with conventional CT imaging or endoscopy. 8, 9 Metabolic change as seen on PET scan may be the most sensitive and quantitative method to determine response to treatment. Numerous studies investigating the predictive value of FDG-PET scanning after completion of preoperative therapy in patients with gastroesophageal cancers have identified a positive correlation with histologic response. [5] [6] [7] 10 Moreover, PET response criteria (PER-CIST) have been proposed to standardize assessment of PET responses. 11 Components of the proposed PERCIST criteria include assessing normal reference tissue values, using a consistent PET protocol, using a fixed small ROI in the most active region of metabolically active tumors, assessing tumor size, and deferring cases that do not have 18F-FDG avidity or are technically unsuitable. We evaluated all PET images in the present study using similar criteria. In doing so, we identified a significant relationship between SUV max response and histologic tumor response for patients with GEJ cancers (rho ¼ 0.19, P ¼ 0.04) and gastric cancers (rho ¼ 0.44, P < 0.0001). We suspect that this relationship was weaker for patients with GEJ cancers because of the near-uniform use of radiation as a component of neoadjuvant therapy in this cohort of patients. Radiotherapy has previously been demonstrated to obfuscate the relationship between metabolic response and histologic tumor response in patients with esophageal cancer when added to chemotherapy-only protocols. 3, 12 Our second aim in undertaking this study was to determine whether associations exist between changes in SUV max after neoadjuvant therapy and outcomes for patients with GEJ and gastric cancers. Many studies have demonstrated a significant association between the change in PET and clinical outcomes. For example, Javeri et al. 13 examined 151 consecutive patients with GEJ adenocarcinoma treated at MD Anderson Cancer Center using chemoradiation, and reported an SUV response of >52% to be associated with improved overall survival (OS). However, traditional staging variables such as T-stage and N-stage were not included in the multivariate analysis. 13 At our own institution, we previously conducted a prospective trial evaluating the role of PET response to predict treatment response in patients with esophageal cancer and identified that a decrease in SUV >60% was associated with improved disease-free and OS, albeit not quite achieving statistical significance.
14 It is important to note however that this study also did not evaluate PET responses in a multivariable fashion in the context of histopathologic data. In our present study, which is the largest from our institution, we found associations between histologic tumor response and DSS for patients with both GEJ and gastric cancers, but failed to identify any significant correlation with SUV max variables (baseline, preoperative or response). A significant strength of the present study is that we exhausted multiple attempts to identify a correlation with changes in SUV max response and DSS, including the use of SUVmax as a continuous variable, use of median values, and the use of a pre-defined cut-off value of 35%. A significant problem with interpreting responses on PET imaging has been that clear and reproducible cut-off values are lacking. SUV max response will need to be standardized if it is to play any role in counseling patients regarding their individual outcomes, although we believe it is exceedingly unlikely that biologically relevant cut-points exist. In order to evaluate the ability of changes in SUV max response to predict outcomes in the context of histopathologic data, we first generated bivariate models using histologic tumor response and SUV max response for patients with GEJ and gastric cancers. In doing so, we identified a prognostic role for histologic response but again failed to identify a prognostic role for SUV max response. Similarly, Lordick et al 2 demonstrated histologic response drives the association with improved survival using bivariate PET/histology in patients undergoing resection for GEJ cancers. Interestingly, Javari et al. identified SUV response as a significant predictor of OS on bivariate analysis, although histologic response was not significant. Perhaps this disparate result stems from the author's reliance on a previously determined cut-point of 52% for change in SUV, which was derived from 24 patients with esophageal squamous cell carcinoma by searching for an SUV cut-off that would result in a sensitivity of 100% for a histologic response.
Next, we attempted to determine if SUV max response could be predictive of outcome when histopathologic data are taken into account. In order to accomplish this aim, we built multivariate histopathologic models separately for gastric and GEJ cancers. Of note, histologic response was no longer significant when pathologic variables were also entered into the model. Following construction of the histopathologic models, we added in SUV max response and again failed to identify a significant role for repeat PET in predicting outcomes for patients when traditional pathologic variables are considered. To date, our study is the first to evaluate PET data following completion of neoadjuvant therapy in the context of conventional postoperative pathologic staging parameters. However, it is not entirely surprising that SUVmax response did not significantly predict outcomes for patients with GEJ and gastric cancers when pathologic variables are given consideration. Ott et al 15 undertook a multivariate analysis on 50 patients undergoing resection for GEJ cancer that included PET response (after 2 weeks of induction therapy), histologic response and pathologic variables. Similar to our results, Ott et al 15 identified that only pathologic nodal status was predictive of OS. Moreover, a recent study of 400 patients with esophageal and GEJ cancers from 2 large centers in the United Kingdom demonstrated that survival is strongly predicted by pathologic stage after neoadjuvant therapy. 16 Our study has important limitations that should be clearly stated. First, our study is retrospective in nature and therefore susceptible to biases inherent to all retrospective studies. Second, it is worth noting that we did not attempt to use extreme outliers (eg, >95% SUV max response) in order to achieve statistical significance in a small subpopulation of patients, as this would almost certainly be useless in any prospectively evaluated population given the retrospective nature of our study. We did however analyze PET SUV max data as a continuous variable, using median cut-off values, as well as a previously published cut-off value (35%). Third, we did not set a minimum SUV max requirement for study entry, but rather provided latitude for the reviewing nuclear medicine physicians to include any patient they felt had PET avid tumors after normalization. Finally, this study does not address the issue of early repeat PET/CT imaging for the purposes of altering treatment. The use of repeat PET/CT imaging at pre-defined time points tied to clinical decisions has not been addressed in the present study. Although a small subset of patients in this study (N ¼ 21) had multiple PET/CTs throughout the course of their preoperative treatment in the context of a prospective clinical trial, these studies in the majority of patients were not obtained at regular intervals and were therefore not comparable between patients. Furthermore, we have noticed that, in some patients undergoing multiple PET/CTs during neoadjuvant treatment, there is variability such that the preoperative SUV max may have been higher than SUVmax measured during treatment.
CONCLUSION
Post-treatment PET is often utilized as a quantitative measure of response to neoadjuvant therapy for patients with GEJ and gastric cancers. If the repeat imaging is undertaken before resection, and not at pre-defined time points tied to clinical decision making, the value of SUV max response must be considered in the context of conventional pathologic staging data. To date, no study has evaluated preoperative PET data in the context of conventional pathologic staging parameters. We therefore sought to ascertain whether quantification of SUV max response yields independent prognostic information. We have demonstrated that changes in SUV max correlate with histologic response. However, despite the use of bivariate and multivariate models, we were unable to define a prognostic role for SUV max response. It is exceedingly unlikely that post-therapy/ preoperative PET will be evaluated in a meaningful prospective manner given the current focus on identifying nonresponders early in the neoadjuvant treatment course. We therefore conclude that the routine use of repeat preoperative PET imaging following neoadjuvant therapy for locoregionally advanced adenocarcinoma of the stomach and GEJ is of limited prognostic value, and should be abandoned, unless being performed in the context of a research setting to assess its value in redirecting neoadjuvant therapy for nonresponders. 
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